2CUREX AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.29 SEK | -13.69% |
|
-28.22% | -85.57% |
| Feb. 29 | 2curex AB Elects Grith Hagel as a New Board Member | CI |
| Feb. 22 | 2cureX AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2021 | 7.39M 682K | Sales 2022 | 3.37M 311K | Capitalization | 143M 13.23M |
|---|---|---|---|---|---|
| Net income 2021 | -18M -1.66M | Net income 2022 | -29M -2.67M | EV / Sales 2021 | 29.9 x |
| Net cash position 2021 | 72.94M 6.73M | Net cash position 2022 | 44.89M 4.14M | EV / Sales 2022 | 29.3 x |
| P/E ratio 2021 |
-14.6
x | P/E ratio 2022 |
-4.81
x | Employees | 14 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 42.42% |
More Fundamentals
* Assessed data
More news
Latest transcript on 2cureX AB
More press releases
| 1 day | -13.69% | ||
| 1 week | -28.22% | ||
| Current month | -36.40% | ||
| 1 month | -23.68% | ||
| 3 months | -83.75% | ||
| 6 months | -89.53% | ||
| Current year | -85.57% |
1 week
0.20
0.39
1 month
0.200.60
Current year
0.202.79
1 year
0.207.28
3 years
0.2023.75
5 years
0.2031.50
10 years
0.2031.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 48 | 21-01-31 | |
Grith Hagel
FOU | Founder | 65 | 05-12-31 |
Ole Thastrup
FOU | Founder | 71 | 05-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ole Thastrup
FOU | Founder | 71 | 05-12-31 |
| Chairman | - | Nov. 13 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 0.29 | -13.69% | 160,520 |
| 24-05-08 | 0.336 | +5.00% | 10,917 |
| 24-05-07 | 0.32 | -18.16% | 491,766 |
| 24-05-06 | 0.391 | -3.22% | 60,868 |
Delayed Quote Nasdaq Stockholm, May 10, 2024 at 11:24 am EDT
More quotes
2cureX AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of diagnostic substances to select treatment for cancer patients. The Company's product candidate, IndiTreat - CRC, aims at optimizing medical treatment for the colorectal cancer patients. Through IndiTreat - CRC, healthcare professionals collect a tumor sample from patients to create a number of three-dimensional micro tumors in order to test available chemotherapies and experimental treatments. The Company's product pipeline includes also IndiTreat - OVA, targeting ovarian cancer treatment, and IndiTreat - KDN, focusing on kidney cancer treatment. It operates through 2cureX A/S.
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -85.57% | 471K | |
| -27.67% | 9.87B | |
| -17.30% | 2.74B | |
| -11.15% | 2.24B | |
| -22.32% | 1.63B | |
| +59.69% | 1.39B | |
| +23.58% | 771M | |
| -1.31% | 760M | |
| -28.57% | 516M | |
| +5.37% | 310M |
- Stock Market
- Equities
- 2CUREX Stock